| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/30/2004 | US20040191247 Use of il-18 inhibitors for treating or preventing cns injuries |
| 09/30/2004 | US20040191242 Method for producing a vaccine |
| 09/30/2004 | US20040191239 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 09/30/2004 | US20040191236 Administering antigen associated with disease, a dendritic cell binding agent specific for the antigen, and an autologous dendritic cell; immunotherapy |
| 09/30/2004 | US20040191219 HSA-free formulations of interferon-beta |
| 09/30/2004 | US20040191210 Compounds |
| 09/30/2004 | US20040191185 Ephedrine or fenfluramine; aluminum foil coated with a thin layer of drug is heated to form vapor; which condenses to form aerosol; rapid peak plasma concentration |
| 09/30/2004 | US20040191184 Delivery of muscle relaxants through an inhalation route |
| 09/30/2004 | US20040191183 Delivery of antiemetics through an inhalation route |
| 09/30/2004 | US20040191182 Delivery of analgesics through an inhalation route |
| 09/30/2004 | US20040191181 Vaporization of diphenhydramine from solid for breathing administerig |
| 09/30/2004 | US20040191180 Breathing analgesics after vaporization for administering pain killer for headaches |
| 09/30/2004 | US20040191179 Breathing antidepressants from aerosols for administering bupropion by heating on a solid support |
| 09/30/2004 | DE10202468A1 Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung Pteridine derivatives, processes for their preparation and their use |
| 09/30/2004 | CA2522176A1 Compositions useful as protein kinase inhibitors |
| 09/30/2004 | CA2520629A1 Methods of promoting the differentiation of stem cells |
| 09/30/2004 | CA2519582A1 Substituted p-diaminobenzene derivatives |
| 09/30/2004 | CA2519444A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 09/30/2004 | CA2519442A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 09/30/2004 | CA2519440A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 09/30/2004 | CA2519372A1 Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators |
| 09/30/2004 | CA2517755A1 Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications |
| 09/29/2004 | EP1462450A1 Substituted morpholine derivatives and their use as therapeutic agents |
| 09/29/2004 | EP1462449A1 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels |
| 09/29/2004 | EP1462447A2 Method for the preparation of pure citalopram |
| 09/29/2004 | EP1462108A1 Interferon g (g) production promoter |
| 09/29/2004 | EP1462103A1 NO donors, combination products and uses as modulators of neurotransmitter release |
| 09/29/2004 | EP1461614A2 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 09/29/2004 | EP1461443A2 Carbohydrate-associated proteins |
| 09/29/2004 | EP1461421A2 A method for the establishment of a pluripotent human blastocyst-derived stem cell line |
| 09/29/2004 | EP1461358A1 Ifnar2 muteins, their production and use |
| 09/29/2004 | EP1461339A2 Spiroazacyclic compounds as monoamine receptor modulators |
| 09/29/2004 | EP1461334A2 Pyrazole derived kinase inhibitors |
| 09/29/2004 | EP1461333A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461332A2 Production of chirally pure alpha-amino acids and n-sulfonyl alpha-amino acids |
| 09/29/2004 | EP1461327A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461326A1 Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors |
| 09/29/2004 | EP1461325A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461323A2 Compounds for the treatment of metabolic disorders |
| 09/29/2004 | EP1461321A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 09/29/2004 | EP1461318A2 Tetrahydroquinoline analogues as muscarinic agonists |
| 09/29/2004 | EP1461311A2 Urea derivatives as vr1-antagonists |
| 09/29/2004 | EP1461165A1 Metallic structures incorporating bioactive materials and methods for creating the same |
| 09/29/2004 | EP1461087A1 Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| 09/29/2004 | EP1461086A2 Enzymatic cleavable reagents for specific delivery to disease sites |
| 09/29/2004 | EP1461070A2 Combined use of a glp-1 compound and a modulator of diabetic late complications |
| 09/29/2004 | EP1461066A1 The use of il6r/il6 chimera in nerve cell regeneration |
| 09/29/2004 | EP1461054A2 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| 09/29/2004 | EP1461043A1 Oral pharmaceutical products containing 17 beta-estradiol-3 lower alkanoate, method of administering the same and process of preparation |
| 09/29/2004 | EP1461042A1 Use of desoxypeganine for treating clinical depression |
| 09/29/2004 | EP1461040A1 Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof |
| 09/29/2004 | EP1461038A1 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 09/29/2004 | EP1461037A2 Beverage treated with nicotine |
| 09/29/2004 | EP1461034A1 Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines |
| 09/29/2004 | EP1461025A1 Treatment of neurodegenerative and cardiovascular disorders |
| 09/29/2004 | EP1461021A1 Transdermal drug delivery system of strychnine, brucine, securinine and their salts |
| 09/29/2004 | EP1461014A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| 09/29/2004 | EP1461013A2 Method of producing a nicotine composition |
| 09/29/2004 | EP1460999A2 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| 09/29/2004 | EP1460995A1 Transdermal transport of compounds |
| 09/29/2004 | EP1392700B1 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta(a)naphthalene |
| 09/29/2004 | EP1390364B1 Aryl-8-azabicyclo 3.2.1]octanes for the treatment of depression |
| 09/29/2004 | EP1385874A4 Alpha conotoxin peptides with analgesic properties |
| 09/29/2004 | EP1303527B1 Matrix metalloproteinase inhibitors |
| 09/29/2004 | EP1299350B1 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness |
| 09/29/2004 | EP1292288B1 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 09/29/2004 | EP1239882B1 Formulations of adenosine a1 agonists and 5ht3 agonists |
| 09/29/2004 | EP1200400B1 Substituted pyrrolidin-2,3,4-trion derivatives useful as nmda-receptor antagonists |
| 09/29/2004 | EP1189905B1 Substituted heterocycle fused gamma-carbolines |
| 09/29/2004 | EP1189881B1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| 09/29/2004 | EP1181713B1 Method for the preparation of pure citalopram |
| 09/29/2004 | EP1181278B1 Cyclic amine derivatives and their uses |
| 09/29/2004 | EP1169302B1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 09/29/2004 | EP1165557B1 ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS |
| 09/29/2004 | EP1153015B1 Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases |
| 09/29/2004 | EP1123295B1 Bicyclic nitrogen heterocycles |
| 09/29/2004 | EP1100483B1 Glucocorticoid-selective anti-inflammatory agents |
| 09/29/2004 | EP1090019B1 Adenosine derivatives |
| 09/29/2004 | EP1083879B1 Devices for providing prolonged drug therapy |
| 09/29/2004 | EP1071418B1 New treatments for nervous disorders |
| 09/29/2004 | EP1019040B1 Aryl ureas for the treatment of inflammatory or immunomodulatory diseases |
| 09/29/2004 | EP0993439B1 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| 09/29/2004 | EP0912533B1 Alkylaminobenzothiazole and -benzoxazole derivatives |
| 09/29/2004 | EP0901487B9 2,3,6 trisubstituted-4(3h)-quinazolinones |
| 09/29/2004 | EP0878199B1 Natural tea comprising alder and mountain ash extracts for treating the effects of alcoholic drinks |
| 09/29/2004 | EP0820456B1 1,2,4-triazolo 4,3-b]pyridazine derivatives and their use |
| 09/29/2004 | EP0713702B1 Anxiolytic agent |
| 09/29/2004 | CN1533399A 免疫调节肽 Immunomodulatory peptides |
| 09/29/2004 | CN1533392A Pyrazolopgrimidinone derivatives having PED 7 inhibitory activity |
| 09/29/2004 | CN1533391A Tricyclic compounds and their uses |
| 09/29/2004 | CN1533387A 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use |
| 09/29/2004 | CN1533382A 哌嗪衍生物 Piperazine derivatives |
| 09/29/2004 | CN1533374A Substitutled cyclohexane-1,4-diamine derivatives |
| 09/29/2004 | CN1533285A Adjuvant combination formulations |
| 09/29/2004 | CN1533284A Use of biologically active HIV-1 Tat, fragments or derivatives thereof for preventing or therapeutic vaccination and/or treating other diseases |
| 09/29/2004 | CN1533283A Use of osteopontin for treatment and/or prevention of neurologic diseases |
| 09/29/2004 | CN1533279A Organo-phosphorous compounds for activating gamma/delta T-cells |
| 09/29/2004 | CN1533278A Naphtothiazine positive allosteric AMPA receptor modulators (PAARM) |
| 09/29/2004 | CN1533276A Use of thiazole derivatives for preparing medicine for protecting mitochondria |
| 09/29/2004 | CN1533270A Oral administered dosage form of GABA anolog prodrugs having reduced toxicity |